Related Experiment Videos
[The no-reflow phenomenon and its clinical significance]
Insights
The no-reflow phenomenon, inadequate blood flow in the heart after procedures, worsens patient outcomes. Early drug intervention can prevent this serious complication.
Area of Science:
- Cardiology
- Vascular Biology
- Interventional Cardiology
Background:
- The no-reflow phenomenon is inadequate myocardial perfusion without mechanical blockage.
- It complicates coronary interventions like angioplasty and bypass surgery.
- This phenomenon worsens clinical outcomes, increasing heart failure and mortality.
Purpose of the Study:
- To review the pathogenesis of no-reflow.
- To discuss current and potential treatments.
- To highlight the rationale for early preventive drug use.
Main Methods:
- Literature review of no-reflow phenomenon.
- Analysis of contributing factors: endothelial dysfunction, rheology, autoregulation.
- Summary of pharmacological interventions.
Main Results:
- No-reflow involves microvascular dysfunction, not just large vessel occlusion.
- Key pathogenetic factors include endothelial changes, altered blood flow properties, and impaired autoregulation.
- Effective treatments involve intracoronary verapamil, adenosine, and systemic agents like nicorandil and glycoprotein IIb/IIIa inhibitors.
Conclusions:
- No-reflow significantly impacts post-procedural cardiac health.
- Understanding its pathogenesis is crucial for effective management.
- Early preventive strategies using specific drugs are vital for at-risk patients, potentially linking to Syndrome X.
Abstract:
The no-reflow phenomenon is characterized by inadequate myocardial perfusion without angiographic manifestations of mechanical vascular occlusion. The phenomenon occurs after coronary vascular interventions (coronary angiography, percutaneous coronary angioplasty, stenting, coronary artery bypass surgery). The development of the no-reflow phenomenon significantly worsens clinical evolution of disease increasing the number of cases of congestive heart failure and hospital mortality. Changes of endothelial function and morphology, changes of blood rheology and microvascular autoregulation are important for pathogenesis of the phenomenon. The treatment include intracoronary introduction of verapamil, adenosine, intravenous introduction of activators of KATP channels (nicorandil), inhibitors of glycoprotein IIb/IIIa receptors. The reasons for early preventive use of intracoronary introduction of verapamil and other drugs in the presence of risk of development of no-reflow phenomenon are presented. The interrelationship between no-reflow phenomenon and syndrome X is also stressed.